Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies

Anna M. Trier, Brian S. Kim

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Atopic dermatitis (AD) is a common inflammatory skin disease characterized by scaly, oozing skin and itch. In moderate-to-severe AD, treatment options have been historically very limited and off-label use has been a common method for disease management. For decades, ciclosporin A was the only systemic immunosuppressive drug approved in most European countries to address this major unmet medical need. However, increased understanding of the pathophysiology of AD has led to a revolution in the treatment of this potentially debilitating disease. Following the approval of the first biological therapy for AD in 2017, there has been a rapid expansion of compounds under development and four additional systemic therapies have been approved in Europe and the USA within the past 3 years alone. In this review, we underscore how key breakthroughs have transformed the therapeutic landscape of AD, leading to a major expansion of type 2 immunity-targeted biological therapies, exploration of neuroimmune modulatory agents, and interest in Janus kinase inhibition.

Original languageEnglish
Pages (from-to)698-708
Number of pages11
JournalBritish Journal of Dermatology
Issue number6
StatePublished - Jun 2023


Dive into the research topics of 'Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies'. Together they form a unique fingerprint.

Cite this